Lecanemab, the first medication designed to remove amyloid beta, a protein believed to cause Alzheimer’s, was developed by Japan’s Eisai Co. and its U.S. partner, Biogen Inc. “We believe ...

In the wake of a market pull in obesity nearly five years ago, the other shoe has dropped for Eisai’s serotonin 2C receptor ...

Eisai (ESAIY) and Biogen (BIIB) announced that the humanized anti-soluble aggregated amyloid-beta, or Abeta, monoclonal antibody Leqembi has ...

Biogen Inc.’s BIIB Japan-based partner, Eisai announced that the European Medicines Agency’s (EMA) Committee for Medicinal ...

(Reuters) -The European Union's drugs regulator on Thursday said it recommends approval of Eisai and Biogen's Leqembi in ...

Reversing an earlier decision, European regulators recommended that an Alzheimer’s therapy from Eisai and Biogen should be ...

Japanese drugmaker Eisai has teamed up with Fujitsu spin-out FCNT, which makes smartphones aimed at older consumers, on digital tools to support people with dementia. Eisai has licensed rights to ...

With the FDA due to deliver a decision of Eisai and Biogen's new Alzheimer's disease candidate lecanemab tomorrow, the safety of the drug has been thrust into the spotlight by a case report ...

We have a specific approach with which we have reduced the question of Eisai's value to a question of the success of the Lenvima and Leqembi products, which for reasons we explained in our first ...

Eisai has lowered the sales forecast for its Alzheimer’s drug Leqembi (lecanemab), primarily citing delays in revenue in the US. The Japanese pharma expects its lead product co-developed with ...

Eisai Inc. announced today that screening for Study E2086-A001-101 (Study 101) to assess the efficacy, safety and tolerability of E2086, a novel selective orexin-2 receptor, is now registered on ...

(RTTNews) - Eisai Co., Ltd. (ESALF.PK) and Biogen Inc. (BIIB) announced a positive opinion has been received from the Committee for Medicinal Products for Human Use (CHMP) of the European ...